secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001437749-25-034095
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed reports Q3 2025 net loss $7.7M; FDA aligned on Phase 3 trial design for neflamapimod in DLB
--------------------------------------------------------------------------------

- Net loss of $7.7M for Q3 2025 vs $4.8M in Q3 2024; cash $27.3M at Sept 30, 2025.
- FDA alignment on design of planned Phase 3 trial of neflamapimod for dementia with Lewy bodies; global pivotal trial initiation targeted H2 2026.
- Phase 2b RewinD-LB 32-week data showed 64% risk reduction in clinically significant worsening on CDR-SB (p<0.001) in DLB patients with low AD co-pathology.
- R&D expenses $6.0M (up $0.9M YoY) primarily due to increased personnel and CMC activities; G&A $2.3M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774925034095/0001437749-25-034095-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774925034095/crvo20251110_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-034095

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer